open-label intent-to-treat population) Exenatide once-weekly ﬁ exenatide once-weekly n= 119Sitagliptin ﬁ exenatide once-weekly n= 130Pioglitazone ﬁ exenatide once-weekly n= 115 Frequent adverse events ( ‡5%) /C160 Diarrhoea 10 (8.4) 12 10 (7.7) 13 9 (7.8) 12Upper respiratory tract infection 7 (5.9) 7 6 (4.6) 7 7 (6.1) 7 Nausea 6 (5.0) 6 14 (10.8) 21 11 (9.6) 13 Vomiting 6 (5.0) 6 5 (3.8) 5 3 (2.6) 4Nasopharyngitis 6 (5.0) 6 3 (2.3) 3 5 (4.3) 6Urinary tract infection 4 (3.4) 4 6 (4.6) 10 7 (6.1) 10 Dyspepsia 0 2 (1.5) 2 7 (6.1) 7 Treatment-emergent adverse events leading to withdrawal /C224 Total 2 (1.7) 4 (3.1) 8 (7.0)Abdominal distension 0 0 1 (0.9) Abdominal pain 0 0 2 (1.7) Alanine aminotransferase increased 1 (0.8) 0 0Blood creatine phosphokinase increased 1 (0.8) 0 0 Cholelithiasis 0 0 1 (0.9) Decreased appetite 0 1 (0.8) 0Hepatitus B surface antigen positive 0 0 1 (0.9)Lipase increased 0 0 1 (0.9) Nausea 0 2 (1.5) 2 (1.7) Rash 0 1 (0.8) 0